Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2012 | 07:41pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
05/26SIGNIFICANT RISE FOR BIOLOGICAL SENS : The report offers a comprehensive evaluat..
AQ
05/25STUDY RESULTS FROM JOHNSON & JOHNSON : Pathways and Mechanisms)
AQ
05/25JOHNSON & JOHNSON : Janssen Pharmaceutical - New Real-World Study Finds Long-Ter..
AQ
05/25JOHNSON & JOHNSON : EU nod for Sandoz Remicade biosimilar Zessly
AQ
05/25JOHNSON & JOHNSON : Jury delivers $25M verdict in Johnson & Johnson asbestos cas..
AQ
05/25JOHNSON & JOHNSON : Absorbs Another Loss in Baby Powder-Mesothelioma Case
AQ
05/25JOHNSON & JOHNSON : Ex-dividend day for
FA
05/24JOHNSON & JOHNSON : Jury awards $25M in Johnson & Johnson baby powder lawsuit
AQ
05/24JOHNSON & JOHNSON : Jury recommends $25M in Johnson & Johnson lawsuit
AQ
05/24JOHNSON & JOHNSON : to Participate in the Jefferies 2018 Global Healthcare Confe..
PU
More news
News from SeekingAlpha
05/263 THINGS IN BIOTECH, MAY 25 : A CLL Game Changer 
05/26Know When To Hold 'Em 
05/25Kezar Life Sciences on deck for IPO 
05/25My Favorite Rule - Don't Put All Your Eggs In One Basket 
05/25WALL STREET BREAKFAST, MAY 25TH : EU Data Privacy Rules Take Effect; U.S. And Ch.. 
Financials ($)
Sales 2018 81 536 M
EBIT 2018 24 881 M
Net income 2018 16 279 M
Debt 2018 9 501 M
Yield 2018 2,97%
P/E ratio 2018 17,99
P/E ratio 2019 16,69
EV / Sales 2018 4,11x
EV / Sales 2019 3,77x
Capitalization 326 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 145 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
MERCK AND COMPANY5.01%158 970
AMGEN2.33%117 942